Johnson & Johnson (NYSE:JNJ) Shares Sold by CCLA Investment Management

CCLA Investment Management reduced its holdings in Johnson & Johnson (NYSE:JNJ) by 1.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 25,871 shares of the company’s stock after selling 264 shares during the period. CCLA Investment Management’s holdings in Johnson & Johnson were worth $4,291,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Scotia Capital Inc. lifted its holdings in Johnson & Johnson by 0.4% during the first quarter. Scotia Capital Inc. now owns 1,307,306 shares of the company’s stock valued at $216,804,000 after purchasing an additional 4,913 shares in the last quarter. Cheviot Value Management LLC increased its stake in shares of Johnson & Johnson by 11.2% during the first quarter. Cheviot Value Management LLC now owns 172,696 shares of the company’s stock worth $26,768,000 after purchasing an additional 17,378 shares in the last quarter. Liberty Wealth Management LLC lifted its stake in Johnson & Johnson by 288.6% in the 1st quarter. Liberty Wealth Management LLC now owns 13,767 shares of the company’s stock valued at $2,283,000 after buying an additional 10,224 shares in the last quarter. Bank of Nova Scotia Trust Co. boosted its holdings in Johnson & Johnson by 0.6% in the 1st quarter. Bank of Nova Scotia Trust Co. now owns 85,641 shares of the company’s stock worth $14,203,000 after buying an additional 494 shares during the last quarter. Finally, J. Safra Sarasin Holding AG boosted its holdings in Johnson & Johnson by 15.0% in the 1st quarter. J. Safra Sarasin Holding AG now owns 369,980 shares of the company’s stock worth $61,357,000 after buying an additional 48,334 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have commented on JNJ. Guggenheim reissued a “neutral” rating and set a $167.00 target price (up previously from $164.00) on shares of Johnson & Johnson in a report on Thursday, July 17th. Wall Street Zen downgraded Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 18th. The Goldman Sachs Group raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $157.00 to $172.00 in a research note on Wednesday, April 9th. Barclays upped their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a report on Thursday, July 17th. Finally, Leerink Partnrs downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 13th. Nine equities research analysts have rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $174.50.

Johnson & Johnson Stock Up 1.6%

Johnson & Johnson stock opened at $167.33 on Friday. The company has a market capitalization of $402.99 billion, a PE ratio of 17.90, a price-to-earnings-growth ratio of 2.13 and a beta of 0.41. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The firm has a 50 day moving average price of $157.46 and a 200 day moving average price of $156.68.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The business had revenue of $23.74 billion during the quarter, compared to analysts’ expectations of $22.85 billion. During the same period in the previous year, the firm posted $2.82 earnings per share. The company’s revenue was up 5.8% on a year-over-year basis. Research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 3.1%. Johnson & Johnson’s dividend payout ratio is 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.